Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- X4 Pharmaceuticals targets 2028 data readout for neutropenia drug
- X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
Vanguard, 13GSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
